All News
Filter News
Found 90 articles
-
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
8/3/2021
"We delivered strong performance this quarter, with volume-driven growth across our core business and most major geographies.
-
Clinical Catch-Up: June 28-July 2
7/6/2021
It was another busy week for clinical trial news ahead of the July 4 holiday in the U.S. Here’s a look. -
Boehringer, Lilly: Jardiance Significantly Reduced CV Death and HF-Related Hospitalization in HFpEF
7/6/2021
Jardiance most recently received approval by the European Commission for the treatment of adult patients with HF with ejection fraction, based on findings from the EMPEROR-Reduced trial. -
Latest Data From SURPASS Trials Demonstrate Tirzepatide Provided Meaningful Blood Sugar Reductions And Weight Loss
6/29/2021
Data from the SURPASS global clinical development program for Eli Lilly and Company's tirzepatide, a novel investigational once-weekly medication for the treatment of type 2 diabetes, demonstrates statistically significant A1C and weight reductions versus several comparators.
-
Eli Lilly and Novo Nordisk published their data in The Lancet Diabetes & Endocrinology and presented them at the ADA conference.
-
Lilly's SURPASS-1 results published in The Lancet show tirzepatide's superior A1C and body weight reductions versus placebo in adults with type 2 diabetes
6/26/2021
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes after 40 weeks of treatment in Eli Lilly and Company's SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo.
-
Lilly's SURPASS-2 results published in The New England Journal of Medicine show tirzepatide achieved superior A1C and body weight reductions compared to injectable semaglutide in adults with type 2 diabetes
6/25/2021
Tirzepatide led to superior A1C and body weight reductions from baseline compared to injectable semaglutide 1 mg in 40-week results from Eli Lilly and Company's (NYSE: LLY) SURPASS-2 clinical trial, which were simultaneously published today in The New England Journal of Medicine (NEJM)1
-
Lilly Announces Webcast to Provide Diabetes Portfolio Update at ADA
6/11/2021
Eli Lilly and Company (NYSE: LLY) will host a webcast on Thursday, July 1, 2021 to discuss the company's diabetes portfolio and its presentations at the American Diabetes Association's Virtual 81st Scientific Sessions.
-
Eli Lilly's SURPASS-4 trial program shows tirzepatide, significantly reduced blood glucose levels and body weight better than insulin glargine in adult patients with type 2 diabetes.
-
Lilly's tirzepatide achieves all primary and key secondary study outcomes against insulin glargine in adults with type 2 diabetes and increased cardiovascular risk in SURPASS-4 trial
5/20/2021
SURPASS program has now met regulatory submission requirements for evaluating cardiovascular risk; Lilly intends to submit registration package to regulatory authorities by the end of 2021
-
What makes this particularly surprising is that in July 2020, mirikizumab hit all primary endpoints against placebo and secondary endpoints against Novartis’ Cosentyx in a Phase III OASIS-2 study of plaque psoriasis.
-
Lilly Delivers First-Quarter 2021 Financial Results, Adjusts 2021 Financial Guidance
4/27/2021
2021 EPS guidance lowered to be in the range of $7.03 to $7.23 on a reported basis and adjusted to be in the range of $7.80 to $8.00 on a non-GAAP basis.
-
Lilly’s tirzepatide has been proposed as a potentially effective treatment option that may rival the efficacy of semaglutide.
-
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes
3/4/2021
Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and Company's (NYSE: LLY) 40-week SURPASS-2 clinical trial.
-
Clinical Catch-Up: February 15-19
2/22/2021
It was a busy week for clinical trial announcements. Here’s a look. -
In Phase III studies, Eli Lilly’s tirzepatide led to significant A1C and body weight reductions from baseline in adults with type 2 diabetes.
-
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
2/17/2021
In the 52-week SURPASS-3 study - the longest in the program to date - the highest dose of tirzepatide reduced A1C by 2.37 percent and body weight by 12.9 kg (28.4 lb., 13.9 percent)
-
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
1/29/2021
Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent.
-
Late-Stage Trial Results Show Promise for Eli Lilly’s Tirzepatide as Treatment for Type 2 Diabetes
12/9/2020
Topline results from the Phase III SURPASS-1 trial show that a 40-week treatment with Eli Lilly's tirzepatide led to significant reductions in A1c and body weight in adults with type 2 diabetes. -
Lilly's tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes
12/9/2020
Tirzepatide led to superior A1C and body weight reductions from baseline in adults with type 2 diabetes after 40 weeks of treatment in topline results from Eli Lilly and Company's (NYSE: LLY) SURPASS-1 monotherapy clinical trial evaluating the efficacy and safety of tirzepatide compared to placebo